Best match
All
Search in:AllTitleAbstractDescription
Publications
Patents
Grants
Pathways
Clinical trials
(6)
Clinical trial
Last Verified: May/31/2020
First Submitted: July/31/2019
First Posted: August/20/2019
Last Update Posted: June/17/2020
Sponsors: The University of Texas Health Science Center at San Antonio
Status: Recruiting
Description

Up to 40 potential candidates will be pre-screened to identify eligible men and women ages 65 years and over with a clinical diagnosis of early AD on a stable dose of cholinesterase inhibitors for at least 3 months (for example, Aricept).

Eligible participants will undergo laboratory assessments of blood and urine, receive study medications over a twelve week period, and complete pre- and post-treatment testing including: an MRI for digital imaging of the brain; lumbar puncture to obtain cerebrospinal fluid; memory and thinking assessments; quality of life questionnaires; and tests of walking, balance and strength, all of which will be done for research purposes only.

Participants must be accompanied by a Legally Authorized Representative and have no travel plans for 4-5 months that would interfere with study visits.

Condition or disease
Condition or disease: Alzheimer Disease
Location
United States
Phase
Phase 1/Phase 2
Study design
Study type:Interventional
Eligibility Criteria
Ages Eligible for Study:65 Years to 65 Years
Sexes Eligible for Study:All
Accepts Healthy Volunteers:Yes
Pulse
Views:
5
Posts:
No posts
Rating:
Not rated
Clinical trial
Last Verified: April/30/2020
First Submitted: December/2/2019
First Posted: December/25/2019
Last Update Posted: May/27/2020
Sponsors: Steadman Philippon Research Institute
Status: Recruiting
Description

This is a Phase I/II randomized, double-blind, placebo-controlled clinical trial that will be conducted at The Steadman Clinic (TSC) and Steadman Philippon Research Institute (SPRI). The purpose of this study is to evaluate the clinical efficacy of Fisetin (FIS), a dietary supplement, in symptomatic knee osteoarthritis (OA) patients. Key aspects of this proposal include the investigator's well-developed methodologies to measure and compare systemic senescence-associated secretory phenotype (SASP) including inflammatory biomarkers and senescent cells, and collect magnetic resonance images, self-reported outcomes, physical performance and other objective clinical data. Given the drug FIS has been empirically demonstrated to reduce senescent cell burden, the main objective(s) are to determine 1) the safety of FIS during dosing and 2) whether FIS reduces senescent cells, pro-inflammatory and cartilage degenerating SASP markers, and reduces OA-symptoms leading to improved joint health and function.

Condition or disease
Condition or disease: Osteoarthritis, Knee
Location
United States
Phase
Phase 1/Phase 2
Study design
Study type:Interventional
Eligibility Criteria
Ages Eligible for Study:40 Years to 40 Years
Sexes Eligible for Study:All
Accepts Healthy Volunteers:Yes
Pulse
Views:
8
Posts:
No posts
Rating:
Not rated
Clinical trial
Last Verified: June/30/2020
First Submitted: March/16/2020
First Posted: March/17/2020
Last Update Posted: July/20/2020
Sponsors: Sundeep Khosla, M.D.
Status: Recruiting
Abstract

To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.

Condition or disease
Condition or disease: Healthy
Location
United States
Phase
Phase 2
Study design
Study type:Interventional
Eligibility Criteria
Ages Eligible for Study:70 Years to 70 Years
Sexes Eligible for Study:Female
Accepts Healthy Volunteers:Yes
Pulse
Views:
9
Posts:
No posts
Rating:
Not rated
Clinical trial
Last Verified: June/30/2020
First Submitted: July/14/2020
First Posted: July/19/2020
Last Update Posted: July/19/2020
Sponsors: Mayo Clinic
Status: Enrolling by invitation
Description

To determine if Fisetin treatment can prevent deterioration of oxygenation status as measured by S/F ratio: SpO2/ FiO2, as well as prevent deterioration in physical function (frailty) and hyper-inflammation, other measures of oxygenation status (progression to supplemental oxygen requirement, assisted breathing/ ventilation), and progression from mild/ moderate to severe/ critical proven COVID-19 (CoV) infection (WHO/NIH Baseline Severity Classification) in non-ICU hospitalized patients and to evaluate the safety and tolerability of Fisetin in this patient population.

Condition or disease
Condition or disease: COVID-19
Location
United States
Phase
Phase 2
Study design
Study type:Interventional
Eligibility Criteria
Ages Eligible for Study:60 Years to 60 Years
Sexes Eligible for Study:All
Accepts Healthy Volunteers:Yes
Pulse
Views:
8
Posts:
No posts
Rating:
Not rated
Clinical trial
Last Verified: June/30/2020
First Submitted: November/18/2015
First Posted: January/10/2016
Last Update Posted: July/21/2020
Sponsors: Mayo Clinic
Status: Recruiting
Description

HSCT survivors are at an increased risk for premature aging. No one has evaluated the biologic markers of premature aging and senescence in HSCT survivors and their correlation with clinical outcomes, lifestyle, and nutrition. The investigators will evaluate age-related changes in HSCT survivors, with specified measures of premature aging, and employ therapeutic opportunities based on targeting senescent cells by conducting the first in-human pilot study of senolytic drugs (in HSCT survivors utilizing a combination of senolytics).

Condition or disease
Condition or disease: Stem Cell Transplant
Location
United States
Phase
-
Study design
Study type:Interventional
Eligibility Criteria
Ages Eligible for Study:18 Years to 18 Years
Sexes Eligible for Study:All
Accepts Healthy Volunteers:Yes
Clinical trial
Last Verified: June/30/2020
First Submitted: March/21/2016
First Posted: July/27/2016
Last Update Posted: July/21/2020
Sponsors: Mayo Clinic
Status: Enrolling by invitation
Description

The proposed studies will examine cellular senescence and the effect of senolytic therapy on senescent cell burden, frailty, and adipose-derived mesenchymal stem cell function in individuals with diabetic chronic kidney disease.

Condition or disease
Condition or disease: Chronic Kidney Disease
Location
United States
Phase
Phase 2
Study design
Study type:Interventional
Eligibility Criteria
Ages Eligible for Study:40 Years to 40 Years
Sexes Eligible for Study:All
Accepts Healthy Volunteers:Yes
Pulse
Views:
1
Posts:
No posts
Rating:
Not rated